Red Nucleus (“RN”), a premier provider of learning, performance, and process solutions for the life sciences industry, announced that it has acquired INVIVO Communications (“INVIVO”), a leading digital scientific communications agency. The INVIVO deal positions Red Nucleus as a differentiated life science firm, grounded in commercial education, clinical operations, R&D process, and now scientific communications. The combined business now has 360+ employees who collectively have over 100 advanced scientific degrees, and covers seven locations across North America, Europe, and Asia.
“We are very excited to partner with Red Nucleus not only because of their global footprint and complimentary capabilities and products we can build on, but because our mission and cultures are so well aligned. This partnership will ultimately provide our clients with greater value across all divisions of the healthcare industry,” commented Andrea Bielecki, INVIVO CEO, who will stay on as a member of the Red Nucleus leadership team.
Since 1998, INVIVO has established itself as a leading digital scientific communications agency that integrates deep therapeutic knowledge and insightful medical strategy with cutting-edge technology. With a track record of long-tenured relationships with global pharmaceutical companies, INVIVO’s core capabilities further augment Red Nucleus’s strengths in strategy and change, clinical operations, and learning and development that will now support clients throughout the entire drug lifecycle.
“We are delighted to add INVIVO to the Red Nucleus family. Our clients have been asking for expanded capabilities, and with the addition of INVIVO, we can now provide a full suite of products and services and the highest level of subject matter expertise to ensure our clients’ success,” said Red Nucleus CEO Ian Kelly. “We are thrilled to partner with the brilliant INVIVO team to bring our clients best-in-class digital scientific communications offerings.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace